Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities

Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) and could expand PrEP usage. Given price differentials between CAB‐LA and TDF/FTC, evaluating the cost‐effectiven...

Cijeli opis

Bibliografski detalji

Glavni autori:	Jesse A. Heitner, Sarah E. Stansfield, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Yiqing Xia, Mathieu Maheu‐Giroux, Ruanne V. Barnabas, Marie‐Claude Boily, Dobromir T. Dimitrov
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2026-01-01
Serija:	Journal of the International AIDS Society
Teme:	cabotegravir cost‐effectiveness analysis emtricitabine tenofovir disoproxil fumarate drug combination HIV prevention men who have sex with men PrEP
Online pristup:	https://doi.org/10.1002/jia2.70061
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!